28 November 2023, Lee's Pharmaceutical Holdings Limited ("Lee's Pharm" or the "Group", HKEx:00950) announced that the Drug Registration Certificate for Adasuve® (Loxapine for Inhalation) had been obtained from the China National Medical Products Administration (“NMPA”) for the acute treatment of agitation associated with schizophrenia or bipolar disorder in adults.

11 November 2023, the “Rare Diseases Symposium” organized by Rare Disease Hong Kong (RDHK) was successfully held with the theme of "Healthy China, leaving no one behind: how Hong Kong can keep up the pace of the Mainland’s rare disease policy". The symposium brought together experts in the field of rare diseases, representatives from the biotechnology sector and rare disease patients/caregivers from Hong Kong and the Mainland, to explore how Hong Kong can draw on the progress made in the Mainland to proactively address the challenges of rare diseases and to provide better diagnosis, treatment and support to patients. Dr LI Xiaoyi, founder of Lee's Pharmaceutical Holdings Limited ("Lee's Pharm" or the "Group", HKEx:00950), was invited to participate in the expert discussion session of the symposium.

The 6th China International Import Expo (CIIE) was successfully held in Shanghai on 5-10 November 2023. As the world's first import-themed national exhibition, it has attracted much attention from domestic and foreign enterprises, governments and consumers since it was first held in 2018. The Sixth CIIE had the largest scale ever with over 400 new products, technologies and services on display. More and more exhibitors regard it as an excellent platform to showcase their latest achievements.

The Hong Kong International Biotechnology Forum and Exhibition (BIOHK2023), organized by the Hong Kong Biotechnology Organization, was successfully held at the Hong Kong Convention and Exhibition Centre (HKCEC) on 13-16 September 2023. It is one of Asia’s largest international biotechnology conventions which aims to facilitate the exchange of ideas among international industry players and foster biotechnology innovation in Hong Kong. Lee's Pharmaceutical (HK) Limited ("Lee's Pharm" or the "Group", HKEx:00950), as a Silver Sponsor, continued to support the event and was honored with the "Best Pharmaceutical Company of the Year Award".

The Department of Economy and Information Technology of Anhui Province recently announced the first batch of the list of Innovative Small and Medium-sized Enterprises (SMEs) for 2023. After several rounds of selection, Zhaoke Pharmaceutical (Hefei) Company Limited ("Zhaoke-Hefei"), a subsidiary of Lee's Pharmaceutical Holdings Limited ("Lee's Pharm" or the "Group", HKEx:00950), was successfully recognized as an innovative SME, and became a part of the gradient cultivation system for high-quality SMEs in Anhui Province.

Dr. Li Xiaoyi, the founder of Lee's Pharmaceutical Holdings Limited ("Lee's Pharm" or "the Group", HKEx:00950), was recently interviewed by Guangdong New Focus, a TV program of Guangdong Radio and Television, in which he explained the Group’s key to success since its establishment was “Focus, Innovation and Excellence”. Please click on the video below to watch the full interview.

June 28, 2023, the award ceremony of the 1st Greater Bay Area Excellent ESG Enterprise Election was held in Guangzhou, which was guided by Guangdong Federation of Industry and Commerce and co-organized by Guangdong Xinkuaibao Agency and Protron Consulting Group. After preliminary professional rating and public voting, Lee's Pharmaceutical Holdings Limited ("Lee's Pharm" or "the Group", HKEx:00950) was honored with the "Most Popular (ESG) Enterprise Award in the Greater Bay Area".

The 2023 China Medical and Health Industry Symbiosis Conference, organized by Menet, a healthcare information platform, was grandly held in Huzhou from 27 to 30 July, 2023. A number of lists were released during the conference, including the “China Pharmaceutical Industry Top 100 Series List” and the “Most Valuable Product in Partnership for Drug Store Chain”.

May 23, 2023, the Provincial Center for ADR Monitoring and the Provincial Medical Products Administration visited Zhaoke Pharmaceutical (Hefei) Company Limited ("Zhaoke Hefei"), a subsidiary of Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm” or “the Group”, HKEx:00950), to conduct on-site assessment. More than 10 pharmaceutical enterprises in Hefei were also invited, including representative enterprises which manufacture drugs selected for VBP, biological medicinal products and Chinese medicine preparations.

May 13, 2023, Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm” or “the Group”, HKEx:00950) successfully held The 8th Pulmonary Arterial Hypertension Summit in Chongqing. With the theme of “Protecting Heart and Lungs For Health”, the forum aimed to promote academic exchanges at home and abroad, and to improve the diagnosis and treatment of pulmonary arterial hypertension.

May 9, 2023, the high-profile 86th PharmChina was grandly opened at the Qingdao International Expo Center on the theme "Building a new innovative and inclusive ecology of pharmaceutical and health". Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm” or “the Group”, HKEx:00950) participated in the event.

April 24, 2023, Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm” or “the Group”, HKEx:00950) announced that its in-licensed product Natulan® (Procarbazine Hydrochloride Capsules, formerly known as Procarbazine), was successfully launched in China and was distributed from its Guangzhou Nansha manufacturing site across the country.